Multi Specific Antibodies Market: By Type (Bispecific Antibody, Tri specific Antibody, Tetra specific Antibody, Multi Specific Antibody), By Drug– (Multispecific (Amivantamab, Blinatumomab), Bispecific (Glofitamab, Epcoritamab, Mosunetuzumab, Teclistamab, Faricimab, Tebentafusp, Emicizumab)), By Indication (Autoimmune Disorders, Genetic Disorders, Haematological Malignancies, Ophthalmic Disorders, Skin Cancers, Solid Tumours), By End User (Hospital, Pharmacies, Others) and Geography    

Multi-Specific Antibodies Market size was valued at USD 5.6 billion in 2023 and is poised to grow at 9.5% CAGR over the forecast period from 2024 to 2030. Driven by the rising interest in R&D activities and growing need for effective medicines, the multi-specific antibody therapies market in terms of therapeutic areas, the market is expected to be driven by medications that treat cancer The rising incidence of chronic diseases, such as oncological disorders, autoimmune disorders, and infectious diseases, is expected to create demand for Multi specific antibody therapies. Such therapies offer a promising approach since they target many disease pathways at the same timeframe. Currently, two multi specific antibodies are under development to treat haematological malignancies and non-small cell lung cancer.

On March 1, 2024, Janssen Biotech, Inc., received FDA approval for amivantamab-vmjw (Rybrevant) with carboplatin and pemetrexed as a first-line treatment for locally advanced or metastatic non-small cell lung cancer. Antibody engineering has been a key driver of the multi-specific antibody business. In recent years, immense progress has been achieved in the development of novel antibody formats and engineering approaches that allow to produce Multi specific antibodies with increased efficacy and stability. For example, breakthroughs in recombinant DNA technology and protein engineering have enabled the development of bispecific antibodies with enhanced pharmacokinetics, less immunogenicity, and higher tumour penetration. The newest prospects in the Multi specific antibody market are primarily driven by increased demand for targeted and personalized medicines, as well as the advent of novel multi specific antibody formats and technologies. The increasing interest in novel Multi specific antibody formats and technology represents a significant opportunity for the multi specific antibody market.

Multi Specific Antibodies Market Key Developments:

• On March 1, 2024, Janssen Biotech, Inc received FDA approval for amivantamab-vmjw (Rybrevant) with carboplatin and pemetrexed as a first-line treatment for locally advanced or metastatic non-small cell lung cancer.
• On June 15, 2023, The FDA has approved Genentech's Columvi (Glofitamab), the first and only bispecific antibody with a fixed duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma.